Enlight Medical is developing invasive and non-invasive BCIs to help replace, restore, or improve human functions.
Enlight Medical has partnered with Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, to accelerates commercial availability of Seer’s Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.
Enlight Medical was founded in Boston, Massachusetts, the United States. It is a stable and rapidly growing global medical technology company, focusing on interventional medical devices for structural heart diseases and intravascular diseases, as well as neuromodulation products. The company has established R&D centers or production bases in Boston, San Francisco, Shanghai, Beijing and Shenzhen, and all of its production workshops comply with GMP standards.
2021年11月3日，應(yīng)脈醫(yī)療科技（上海）有限公司的NovoClasp?經(jīng)導(dǎo)管二尖瓣夾及可操控導(dǎo)引導(dǎo)管系統(tǒng)在首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院完成首例人體植入。本例手術(shù)由首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院院長張宏家教授、中國醫(yī)學(xué)科學(xué)院阜外醫(yī)院吳永健教授現(xiàn)場指導(dǎo)，首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院心臟瓣膜病介入中心宋光遠(yuǎn)教授團(tuán)隊、超聲科何怡華教授團(tuán)隊完成，香港亞洲心臟中心林逸賢教授提供遠(yuǎn)程輔助，為一位高齡重度二尖瓣反流的患者成功實(shí)施微創(chuàng)介入二尖瓣緣對緣修復(fù)手術(shù)。本例手術(shù)的成功標(biāo)志著NovoClasp?二尖瓣修復(fù)系統(tǒng)順利開展首次人體臨床研究入組。
2021年10月18日，應(yīng)脈醫(yī)療宣布完成數(shù)億人民幣B輪融資，本輪融資由國投招商、海松資本及前海母基金共同領(lǐng)投，楹聯(lián)健康基金跟投，原股東高瓴創(chuàng)投、惠每資本、真格基金、辰德資本繼續(xù)增持。
2021年9月13日~9月17日，中國結(jié)構(gòu)周國際頻道特別推出“Device To World中國器械走向世界——創(chuàng)新論壇圓桌會”。作為中國結(jié)構(gòu)周首個醫(yī)械國際交流論壇，通過圓桌討論的形式，讓全球的專家學(xué)者認(rèn)識和了解中國原創(chuàng)器械的風(fēng)采與優(yōu)勢。會上，NovoClasp?二尖瓣系統(tǒng)作為本場首發(fā)國產(chǎn)器械驚艷亮相，受到了國內(nèi)外專家的關(guān)注與褒贊。
@Copyright 2020-2022 Enlight Medical Limited All rights reserved 滬ICP備20012889號-2
